Ensuring stable supply and safety during the COVID-19 pandemic
First written in FY2021-Q1. 7 of 9 entries say "Restated". Latest entry: FY2024-Q1.
115 other companies' latest entry also says "Restated".
- FY2024-Q1RestatedAnnual report
「The Group is working to maintain a stable supply of pharmaceuticals and other products while ensuring the safety of its business partners and Group employees, in order to fulfill its mission as social infrastructure handling products related to human life.」
Even amid concern about a renewed spread of infection, the Company continues to ensure the safety of business partners and employees and maintain a stable supply of pharmaceuticals and other products. - FY2023-Q2RestatedAnnual report
「As the COVID-19 pandemic continues for an extended period, the Company is working to maintain a stable supply of pharmaceuticals, deliver COVID-19 vaccines and therapeutic drugs, and address shortages and supply-demand adjustments for generic pharmaceuticals.」
During the pandemic, the Company continues to maintain a stable supply of pharmaceuticals, deliver vaccines and therapeutic drugs, and address shortages and supply-demand adjustments for generic pharmaceuticals. - FY2023-Q1RestatedAnnual report
「As a social infrastructure provider handling products essential to life, we are taking measures to prevent the further spread of infection while ensuring the safety of our business partners and Group employees and working to maintain a stable supply of pharmaceuticals and other products.」
As the pandemic continues for an extended period, the Company continues to prevent a renewed spread of infection, ensure safety and maintain a stable supply of pharmaceuticals and other products. - FY2022-Q3RestatedAnnual report
「As the spread of COVID-19 continued, the Group prioritized its business activities involving the stable supply of pharmaceuticals and the delivery of COVID-19 vaccines and treatments, while taking every precaution to prevent infection.」
As part of its response during the pandemic, the Company is giving top priority to delivering vaccines and therapeutic drugs, in addition to maintaining a stable supply of pharmaceuticals. - FY2022-Q2RestatedAnnual report
「As the spread of COVID-19 continued, the Group prioritized its business activities involving the stable supply of pharmaceuticals and the delivery of COVID-19 vaccines and treatments, while taking every precaution to prevent infection.」
As part of its response to maintaining stable supply during the pandemic, the Company is giving top priority to delivering vaccines and therapeutic drugs. - FY2021AdvancedAnnual report
「In establishing the distribution system for COVID-19 vaccines promoted by the government, 6 of the Company’s consolidated subsidiaries were selected as designated wholesalers. Through the distribution of COVID-19 vaccines and related products, the Group will help facilitate smooth vaccination and thereby contribute to protecting people’s lives.」
The response to maintaining stable supply during the COVID-19 pandemic took concrete form through the selection of 6 consolidated subsidiaries as designated vaccine wholesalers and their cooperation in distributing vaccines and related products. - FY2021-Q3RestatedAnnual report
「The Group took measures to prevent the spread of infection and worked to ensure a stable supply of pharmaceuticals and other products while securing the safety of its business partners and Group employees.」
The Company continues to prevent infection, ensure safety and maintain stable supply during the COVID-19 pandemic. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter of the fiscal year under review, as the COVID-19 pandemic continued, the Group took measures to prevent the spread of infection and worked to ensure a stable supply of pharmaceuticals and other products while ensuring the safety of business partners and Group employees, in order to fulfill its mission as social infrastructure handling life-related products.」
The Company continues to prevent the spread of infection, ensure the safety of business partners and employees, and maintain a stable supply of pharmaceuticals and other products during the pandemic. - FY2021-Q1First statedAnnual report
「As a social infrastructure provider handling products related to human life and health, the Group is taking measures to prevent the spread of infection and working to ensure a stable supply of pharmaceuticals and other products while securing the safety of its business partners and Group employees.」
The Company identified preventing the spread of infection, ensuring the safety of business partners and employees, and maintaining a stable supply of pharmaceuticals and other products as specific measures during the pandemic.